The DOI matches its Crossref record; 97 of the 99 references it cites were found in a registry or an index.
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia
Open accessAbstract
Background The etiology of dementia that occurs in patients with schizophrenia is not well understood. Nicotinic acetylcholine receptors have been implicated in cognitive function, and deficits in these receptors have been reported in schizophrenia.Methods The present study investigates possible associations of nicotinic receptor subunit expression in the dorsal lateral prefrontal cortex, an area known to be affected in schizophrenia, and dementia rating.Results alpha7 immunoreactivity was reduced by 20% to 28% and [(3)H]epibatidine binding was increased twofold in groups of patients with schizophrenia compared to normal control subjects matched for age, postmortem delay, and low levels of brain nicotine and cotinine. In contrast, no significant differences in alpha4, alpha3, or beta2 immunoreactivity or alpha7 messenger RNA expression were observed in schizophrenia patients compared with control subject values. Clinical dementia ratings in patients with schizophrenia were correlated with neither [(3)H]epibatidine binding nor nicotinic receptor subunit expression.Conclusions These data indicate no relationship between the trend for reduced neocortical alpha7 subunit protein expression in schizophrenia and dementia. Further investigations are required to establish whether the reduction in alpha7 protein in the dorsal lateral prefrontal cortex is associated with clinical features other than dementia in schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, anomalies in the availability or expression of specific nAChR subunits have been implicated in depression [104] and schizophrenia patients [105, 106].”
From Adolescent nicotine exposure and persistent neurocircuitry changes: unveiling lifelong psychiatric risks (2025) · cites this paper as [105]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
A review of MRI findings in schizophrenia
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00163-3 · Cited by 2,346
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141
Serotonin-dopamine interaction and its relevance to schizophrenia
Kapur, S., & Remington, G. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 826
Kelley, W. M., Miezin, F. M., McDermott, K. B., Buckner, R. L., Raichle, M. E., Cohen, N. J., Ollinger, J. M., Akbudak, E., Conturo, T. E., Snyder, A. Z., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80474-2 · Cited by 823
Decision-making processes following damage to the prefrontal cortex
Manes, F., Sahakian, B., Clark, L., Rogers, R., Antoun, N., Aitken, M., & Robbins, T. (2002) · Brain · doi:10.1093/brain/awf049 · Cited by 799
Normalization of auditory physiology by cigarette smoking in schizophrenic patients
Adler, L. E., Hoffer, L., Wiser, A., & Freedman, R. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1856 · Cited by 679
Freedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678
Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment
Marks, M., Pauly, Jr., Gross, S., Deneris, E., Hermans-Borgmeyer, I., Heinemann, S., & Collins, A. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-07-02765.1992 · Cited by 551
Research works printed but not linked: 1
- Lukas, 1996, Regulation by nicotine of its own receptors, Drug Dev Res, 38, 136, 10.1002/(SICI)1098-2299(199607/08)38:3/4<136::AID-DDR2>3.0.CO;2-N · DOI
Cited by
Sorted by citations
Neuronal nicotinic receptors: from structure to pathology
Gotti, C., & Clementi, F. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.006 · Cited by 970
Brain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Turetsky, B. I., Calkins, M. E., Light, G. A., D, A. O. M., Radant, A. D., & Swerdlow, N. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl060 · Cited by 575
Sofouglu, M., Herman, A. I., Robinson, C. D., & Waters, A. J. (2014) · Lincoln (University of Nebraska) · Cited by 417
The Influence of Working-Memory Demand and Subject Performance on Prefrontal Cortical Activity
Bart Rypma, A., Berger, J. S., & D’Esposito, M. (2002) · Journal of Cognitive Neuroscience · doi:10.1162/08989290260138627 · Cited by 373
Cognitive Effects of Nicotine: Recent Progress
Valentine, G. W., & Sofuoglu, M. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666171103152136 · Cited by 302
Jones, C. K., Byun, N. E., & Bubser, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.199 · Cited by 241
Smoking, nicotine and neuropsychiatric disorders
Döme, P., Lazáry, J., Kalapos, M. P., & Rihmer, Z. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.013 · Cited by 227
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Nicotinic modulation of neuronal networks: from receptors to cognition
Mansvelder, H. D., van Aerde, K. I., Couey, J. J., & Brussaard, A. B. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0070-z · Cited by 202
Neuromodulation by acetylcholine: examples from schizophrenia and depression
Higley, M. J., & Picciotto, M. R. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.06.004 · Cited by 184
Leiser, S., Bowlby, M., Comery, T., & Dunlop, J. (2009) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2009.03.009 · Cited by 167
Wischhof, L., Irrsack, E., Osorio, C., & Koch, M. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.10.004 · Cited by 172
Systemic Biomarkers of Accelerated Aging in Schizophrenia: A Critical Review and Future Directions
Nguyen, T. T., Eyler, L. T., & Jeste, D. V. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx069 · Cited by 156
Young, J. W., & Geyer, M. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.031 · Cited by 128
Cholinergic connectivity: it's implications for psychiatric disorders
Scarr, E., Gibbons, A. S., Neo, J. H., Udawela, M., & Dean, B. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00055 · Cited by 124
Cholinergic Modulation of Neuroinflammation: Focus on α7 Nicotinic Receptor
Piovesana, R., Intriago, M. S. S., Dini, L., & Tata, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094912 · Cited by 115
Hashimoto, K., Ishima, T., Fujita, Y., Matsuo, M., Kobashi, T., Takahagi, M., Tsukada, H., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.034 · Cited by 102
Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice
Young, J. W., Meves, J. M., Tarantino, I. S., Caldwell, S., & Geyer, M. A. (2011) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2011.00711.x · Cited by 93
Very poor outcome schizophrenia: Clinical and neuroimaging aspects
Mitelman, S. A., & Buchsbaum, M. S. (2007) · International Review of Psychiatry · doi:10.1080/09540260701486563 · Cited by 81
Nicotinic acetylcholine receptors: an overview on drug discovery
D’hoedt, D., & Bertrand, D. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902841045 · Cited by 79
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Coyle, J. T., Balu, D. T., Benneyworth, M. A., Basu, A. C., & Roseman, A. S. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jcoyle · Cited by 75
Greenbaum, L., & Lerer, B. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.59 · Cited by 73
Young, J. W., Meves, J. M., & Geyer, M. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.11.028 · Cited by 69
Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia
Maurus, I., Hasan, A., Röh, A., Takahashi, S., Rauchmann, B., Keeser, D., Malchow, B., Schmitt, A., & Falkai, P. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01025-w · Cited by 68
Evidence for a role of nicotinic acetylcholine receptors in schizophrenia
Catherine, E. A. (2007) · Frontiers in bioscience · doi:10.2741/2424 · Cited by 63
Mathew, S., Law, A. J., Lipska, B. K., Dávila‐García, M. I., Zamora, E. D., Mitkus, S. N., Vakkalanka, R., Straub, R. E., Weinberger, D. R., Kleinman, J. E., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm253 · Cited by 63
Hashimoto, K., Nishiyama, S., Ohba, H., Matsuo, M., Kobashi, T., Takahagi, M., Iyo, M., Kitashoji, T., & Tsukada, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003231 · Cited by 59
Hashimoto, K. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150605111345 · Cited by 53
Novel α7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia
Severance, E. G., & Yolken, R. H. (2007) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00323.x · Cited by 51
REVIEW: Cognitive effects of nicotine: genetic moderators
Herman, A. I., & Sofuoglu, M. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00213.x · Cited by 52
Role of the cholinergic system in the pathology and treatment of schizophrenia
Scarr, E., & Dean, B. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.1.73 · Cited by 41
Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives
Jaco, A. D., Bernardini, L., Rosati, J. D., & Tata, A. M. (2016) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524916666160729111446 · Cited by 40
Duffy, Á. M., Zhou, P., Milner, T. A., & Pickel, V. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.04.024 · Cited by 49
Rycroft, N., Hutton, S. B., & Rusted, J. M. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0455-7 · Cited by 39
Rowe, A. R., Mercer, L., Casetti, V., Sendt, K.-V., Giaroli, G., Shergill, S. S., & Tracy, D. K. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114564096 · Cited by 41
Horti, A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.030 · Cited by 33
Increased antibodies for the α7 subunit of the nicotinic receptor in schizophrenia
Chandley, M., Miller, M. N., Kwasigroch, C. N., Wilson, T. D., & Miller, B. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.01.023 · Cited by 36
Lyukmanova, E. N., Shenkarev, Z. O., Schulga, A. A., Ermolyuk, Y. S., Mordvintsev, D. Y., Utkin, Y. N., Shoulepko, M. A., Hogg, R. C., Bertrand, D., Dolgikh, D. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611263200 · Cited by 35
Georgiou, R., Lamnisos, D., & Giannakou, K. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.779607 · Cited by 37
Coura, R. S., Cressant, A., Xia, J., de Chaumont, F., Olivo‐Marin, J. C., Pelloux, Y., Dalley, J. W., & Granon, S. (2013) · The FASEB Journal · doi:10.1096/fj.13-231084 · Cited by 33
“is controversial and not well established, 2*nAChRs have been shown to be up-regulated in this disorder (70), control epigenetic modifications (71), and also medi-”
BackgroundProxy measures of premortem cognitive aptitude in postmortem subjects with schizophrenia
Glausier, J. R., Kelly, M. A., Salem, S., Chen, K., & Lewis, D. A. (2019) · Psychological Medicine · doi:10.1017/s0033291719000382 · Cited by 33
Ogawa, M., Nishiyama, S., Tsukada, H., Hatano, K., Fuchigami, T., Yamaguchi, H., Matsushima, Y., Ito, K., & Magata, Y. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.11.007 · Cited by 31
Cholinergic system in schizophrenia: A systematic review and meta-analysis
Saint-Georges, Z., MacDonald, J., Al-Khalili, R., Hamati, R., Solmi, M., Keshavan, M. S., Tuominen, L. J., & Guimond, S. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03023-y · Cited by 32
Strube, W., Bunse, T., Nitsche, M. A., Wobrock, T., Aborowa, R., Misewitsch, K., Herrmann, M., Falkai, P., & Hasan, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.275 · Cited by 27
Veselinović, T., & Neuner, I. (2022) · CNS Drugs · doi:10.1007/s40263-022-00935-z · Cited by 31
Acheson, D. T., Twamley, E. W., & Young, J. W. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00103 · Cited by 26
Reynolds, L. M., Faure, P., & Barik, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03110-0 · Cited by 26
“Notably, anomalies in the availability or expression of speci fi c nAChR subunits have been implicated in depression [104] and schizophrenia patients [105, 106].”
Boggs, D. L., Carlson, J., Cortes-Briones, J., Krystal, J. H., & D’Souza, D. C. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131216121019 · Cited by 26
Saur, T., DeMarco, S., Ortiz, A., Sliwoski, G. R., Hao, L., Wang, X., Cohen, B. M., & Buttner, E. A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003313 · Cited by 25
Neves, G. A., & Grace, A. A. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0066-0 · Cited by 26
Othman, A. A., Lenz, R. A., Zhang, J., Li, J., Awni, W. M., & Dutta, S. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010370460 · Cited by 24
Iwata, Y., Nakajima, M., Yamada, K., Nakamura, K., Sekine, Y., Tsuchiya, K. J., Sugihara, G., Matsuzaki, H., Suda, S., Suzuki, K., et al. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.10.002 · Cited by 22
Cameli, C., Bacchelli, E., Paola, M. D., Giucastro, G., Cifiello, S., Collo, G., Cainazzo, M. M., Pini, L. A., Maestrini, E., & Zoli, M. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0223-2 · Cited by 23
Ogawa, M., Tsukada, H., Hatano, K., Ouchi, Y., Saji, H., & Magata, Y. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.337 · Cited by 21
Horti, A., Ravert, H., Gao, Y.-J., Holt, D., Bunnelle, W., Schrimpf, M., Li, T., Ji, J.-G., Valentine, H., Scheffel, U., et al. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.11.013 · Cited by 18
Chronic Nicotine Exposure has Dissociable Behavioural Effects on Control and Beta2−/− Mice
Besson, M., Suárez, S., Cormier, A., Changeux, J., & Granon, S. (2008) · Behavior Genetics · doi:10.1007/s10519-008-9216-1 · Cited by 19
Ogawa, M., Tatsumi, R., Fujio, M., Katayama, J., & Magata, Y. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.12.016 · Cited by 20
Bois, F., Gallezot, J., Zheng, M., Lin, S.-F., Esterlis, I., Cosgrove, K., Carson, R. E., & Huang, Y. H. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.08.003 · Cited by 19
Azimi, M., Oemisch, M., & Womelsdorf, T. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05430-w · Cited by 19
Eickhoff, S., Franzen, L., Korda, A. I., Rogg, H. V., Trulley, V.-N., Borgwardt, S., & Avram, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.909961 · Cited by 17
Severance, E. G., Dickerson, F., Stallings, C. R., Origoni, A. E., Sullens, A., Monson, E. T., & Yolken, R. H. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0164-y · Cited by 16
Kobayashi, S., Toyooka, N., Zhou, D.-J., Tsuneki, H., Wada, T., Sasaoka, T., Sakai, H., Nemoto, H., Garraffo, H., Spande, T., et al. (2007) · Beilstein Journal of Organic Chemistry · doi:10.1186/1860-5397-3-30 · Cited by 2
Beinat, C., Reekie, T. A., Banister, S. D., O’Brien-Brown, J., Xie, T., Olson, T. T., Xiao, Y., Harvey, A. J., O'Connor, S. M., Coles, C. J., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.025 · Cited by 14
PET tracers for imaging brain α7 nicotinic receptors: an update.
Chalon, S., Vercouillie, J., Guilloteau, D., Suzenet, F., & Routier, S. (2015) · Chemical Communications · doi:10.1039/c5cc04536c · Cited by 12
Impact of Nicotine on Cognition in Patients With Schizophrenia: A Narrative Review
Spasova, V., Mehmood, S., Minhas, A., Azhar, R., Anand, S., Abdelaal, S., Sham, S., Chauhan, T. M., & Dragas, D. (2022) · Cureus · doi:10.7759/cureus.24306 · Cited by 13
Hippocampal Availability of the α7 Nicotinic Acetylcholine Receptor in Recent-Onset Psychosis
Wong, N. R., Rubin, L. H., Harrington, C. K., Jenkins, K. R., Shinehouse, L. K., Yoon, M., Kilgore, J. J., Soule, A. R., Lesniak, W. G., Rowe, S. P., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.27163 · Cited by 10
Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study
Aidelbaum, R., Labelle, A., Baddeley, A., & Knott, V. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117746903 · Cited by 10
Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders
Royse, S. K., Lopresti, B. J., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15657 · Cited by 10
Origine et renouveau du concept de démence dans la schizophrénie
Azorin, J., Kaladjian, A., & Fakra, É. (2005) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2005.05.008 · Cited by 10
Sofuoglu, M., Herman, A. I., Robinson, C. D., & Waters, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00012-5 · Cited by 8
Onde P50 dans la schizophrénie
Houy, E., & Thibaut, F. (2007) · Encyclopédie médico-chirurgicale. Psychiatrie · doi:10.1016/s0246-1072(07)48130-5 · Cited by 9
Choueiry, J., Blais, C. M., Shah, D. K., Smith, D., Fisher, D. J., Ilivitsky, V., & Knott, V. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05646-1 · Cited by 9
Smith, D., Fisher, D. J., Blier, P., Ilivitsky, V., & Knott, V. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.07.008 · Cited by 8
T-cell receptors modify neuronal function in the central nervous system
Komal, P., & Nashmi, R. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.023 · Cited by 7
Beinat, C., Banister, S. D., van Prehn, S., Doddareddy, M. R., Hibbs, D. E., Sako, M., Chebib, M., Tran, T. P., Al‐Muhtasib, N., Xiao, Y., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.052 · Cited by 7
Dean, B. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670903270431 · Cited by 7
Suresh, A., & Hung, A. (2019) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25761 · Cited by 5
Alterations of Neurotransmitter Receptors in Schizophrenia: Evidence from Postmortem Studies
Kristiansen, L. V., Cowell, R. M., Biscaia, M., McCullumsmith, R. E., & Meador‐Woodruff, J. H. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_14 · Cited by 5
Telomeres and the ageing process
Woo, J., Suen, E., & Tang, N. L. S. (2010) · Reviews in Clinical Gerontology · doi:10.1017/s0959259809990451 · Cited by 4
Schizophrenia: A Complex Mental Illness
Ordieres, M. G. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-95360-1_33 · Cited by 5
Wakuda, T., Yokokura, M., Magata, Y., Suzuki, C., Murayama, C., Goto, T., Tamayama, T., Kameno, Y., Iwabuchi, T., Isobe, T., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03162-2 · Cited by 3
Chapter 1 Cholinergic components of frontal lobe function and dysfunction
Rabin, L. A., Tanapat, P., & Relkin, N. R. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)88001-8 · Cited by 2
Santos, J. R., Tomaz, P. R. X., Issa, J. S., Gaya, P. V., Abe, T. O., Krieger, J. E., Pereira, A. C., & Santos, P. C. J. L. (2020) · Genes · doi:10.3390/genes11070746 · Cited by 2
Potential role for kynurenine pathway in increased COVID-19 mortality of patients with schizophrenia
Wang, P., Li, Z.-Y., Wang, J., Liu, K.-Z., Wang, Y., Guo, Q., Wen, S., Ni, P.-L., Zhang, Q.-P., Wang, T., et al. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.02.030 · Cited by 1
Nicotinic Receptors in Brain Diseases
Stitzel, J. A. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_22 · Cited by 1
Modulation of prefrontal glutamatergic transmission and "atypicality" of antipsychotic drugs
Konradsson‐Geuken, Å. (2007) · Figshare · Cited by 1
Cholinergic Mechanisms in Schizophrenia
Raedler, T. J., & Freedman, R. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_2 · Cited by 1
Functional Modulation of the Mouse Prefrontal Cortex by Nicotinic Acetylcholine Receptors
Couey, J. J. (2009) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Smith, D. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-4012
A Novel Mechanism for Nicotinic Acetylcholine Receptor Antagonist-Induced Cancer Cell Cytotoxicity
Clarke, M. R. (2016) · Otago University Research Archive (University of Otago)
Tracy, D. K., Casetti, V., Rowe, A. R., Mercer, L., & Shergill, S. S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_42
Vingerhoets (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170323wv
Azimi, M., Oemisch, M., & Womelsdorf, T. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/369496
Central Cholinergic Nervous System and Its Correlates
(2007) · Springer eBooks · doi:10.1007/978-0-387-46526-5_9
Compensatory hallucinogenesis across three neuropsychiatric disorders: a Bayesian account
Vin, R., Galbraith, J., Seabury, R. D., Yi, H. Y., Hernández-Busot, G., Oland, L., Epié, B., Trainer, A. E., Fredericks, C. A., & Powers, A. R. (2026) · Brain Communications · doi:10.1093/braincomms/fcag001 · Cited by 1
Metadata
- Authors
- Martin-Ruiz, C. M., Haroutunian, V. H., Long, P., Young, A. H., Davis, K. L., Perry, E. K., & Court, J. A.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Newcastle University (GB)
- Corresponding author
- Court, Jennifer A
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 54
- Issue
- 11
- Pages
- 1222-1233
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2041781351
- Cited by
- 100
- References
- 99
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 5 · 2017: 3 · 2016: 4 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 2
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institutes of Health (5p01mh045212-05)
- National Institute of Mental Health (MH 45212)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- schizophrenia, dementia, nicotinic acetylcholine receptors, dorsolateral prefrontal cortex, epibatidine binding, receptor subunit expression, Clinical Dementia Rating, cognitive impairment
- MeSH terms
- Aged, Aged, 80 and over, Cotinine, Dementia, Female, Humans, Male, Middle Aged, Nicotine, Psychiatric Status Rating Scales, Pyridines, Radioligand Assay, Receptors, Nicotinic, RNA, Messenger, Schizophrenia, Severity of Illness Index, Smoking, Case-Control Studies, Prefrontal Cortex, Bridged Bicyclo Compounds, Heterocyclic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
